Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28426746 | 0.98 | GBA1 (0.33) | GBA1SIGMAR1 | |
| SCHEMBL10037070 | 0.91 | EPHX2 (0.37) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL15593375 | 0.90 | ACHE (0.38) | SIGMAR1 | |
| SCHEMBL14416818 | 0.90 | GAA (0.34) | GBA1SIGMAR1OPRM1 | |
| SCHEMBL13331319 | 0.90 | GBA1 (0.30) | GBA1 | |
| SCHEMBL18769201 | 0.90 | MAOB (0.41) | — | |
| SCHEMBL24310936 | 0.89 | EPHX2 (0.40) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL22893117 | 0.89 | EPHX2 (0.40) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL22906294 | 0.89 | EPHX2 (0.40) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL22893113 | 0.89 | EPHX2 (0.40) | SIGMAR1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-108699052-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022076621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-7199105-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1654268-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| EP-0718712-B1 | Quaternary phosphonium trihalocuprate salts as charge-control agents for toners and developers | EASTMAN KODAK CO (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0718707-B1 | Quaternary phosphonium trihalozincate salts as charge-control agents for toners and developers | EASTMAN KODAK CO (US) | 1998-03-04 | — | — | EP | disclosed |
| US-5561020-A | THERMALLY STABLE, UNIFORMLY DISPERSIBLE | EASTMAN KODAK COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5547803-A | Quaternary phosphonium trihalocuprate salts as charge-control agents for toners and developers | EASTMAN KODAK COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0718712-A1 | Quaternary phosphonium trihalocuprate salts as charge-control agents for toners and developers | EASTMAN KODAK COMPANY (US) | 1996-06-26 | — | — | EP | disclosed |
| EP-0718707-A1 | Quaternary phosphonium trihalozincate salts as charge-control agents for toners and developers | EASTMAN KODAK COMPANY (US) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | GBA1 3839/4885SIGMAR1 4646/4885CCR3 3485/4885 |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | GBA1 564/4885SIGMAR1 2829/4885CCR3 4016/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | GBA1 4051/4885SIGMAR1 4753/4885CCR3 2052/4885 |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GBA1 827/4885SIGMAR1 2119/4885CCR3 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.